KRAS and familial pancreatic carcinoma: The small guanosine triphosphatase KRAS is frequently mutated in 98% of pancreatic cancers, making it an ideal target for therapeutic intervention.4, 5, 6 Attempts to target this pathway have largely been unsuccessful.